UGN-501

July 8, 2026: UroGen Pharma Ltd. (NASDAQ: URGN) announced the FDA cleared its Investigational New Drug (IND) application for UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The IND clearance enables UroGen to initiate a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501 in NMIBC patients.

The Phase 1 trial is expected to begin in Q4 2026, with planned evaluation of safety, tolerability, and feasibility of intravesical delivery. UroGen describes UGN-501 as designed to selectively replicate in tumor cells to drive direct tumor cell destruction and stimulate an anti-tumor immune response. The company noted nonclinical data showing cytotoxic activity across a broad panel of bladder cancer cell lines spanning multiple disease stages and grades, and said it may explore additional solid tumor indications based on emerging clinical and translational data.